Evaluation of a moisturising micro-gel spray for prevention of cell dryness in oral mucosal cells: an in vitro study and evaluation in a clinical setting

A moisturising micro-gel spray for prevention of dryness was compared with commercial products and artificial saliva in vitro and in a clinical setting in patients with cancer. Survival of cultured human gingival epithelial cells was evaluated after treatment with each product for 15 min. A dry test was performed for products giving a 50% survival rate, in which cell survival was measured after drying of cells treated with each product. The survival rates of cells treated with the micro-gel spray and artificial saliva were significantly higher than those of control cells. The micro-gel spray was then evaluated for 1 week in patients with symptoms of dry mouth caused by cancer treatment. There was significant improvement of these symptoms at night and on awakening and of subjective symptoms of decreased salivary volume (P < 0.05). Mean visual analogue scale scores also significantly decreased (P < 0.01). These data suggest that evaluation of moisturising products for dryness prevention can be performed in cultured cells, since products that performed well in vitro also showed good efficacy for symptoms of dry mouth. The micro-gel spray was particularly effective for relieving symptoms of dry mouth in patients with cancer.

[1]  G. Williamson,et al.  ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL Radiology , 2014 .

[2]  M. Mencoboni,et al.  Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy. , 2011, European journal of cancer care.

[3]  Y. Ota,et al.  Protective effects of polysaccharides and polyhydric alcohols in a dry mouth model in cultured cells , 2011, Supportive Care in Cancer.

[4]  T. Takato,et al.  Trehalose inhibits oral dryness by protecting the cell membrane. , 2010, International journal of oral and maxillofacial surgery.

[5]  K. Harrold.  Effective management of adverse effects while on oral chemotherapy: implications for nursing practice , 2010 .

[6]  E. Choi,et al.  Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies , 2009, European journal of cancer care.

[7]  M. Behr,et al.  Saliva substitutes for the treatment of radiation-induced xerostomia—a review , 2009, Supportive Care in Cancer.

[8]  K. Ohtomo,et al.  Oral pilocarpine (5mg t.i.d.) used for xerostomia causes adverse effects in Japanese. , 2009, Auris, nasus, larynx.

[9]  K. Sultanem,et al.  Phase III randomized study: Oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation‐induced xerostomia , 2009, Head & neck.

[10]  I. Chitapanarux,et al.  Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial. , 2008, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[11]  J. Gil-Montoya,et al.  Evaluation of the clinical efficacy of a mouthwash and oral gel containing the antimicrobial proteins lactoperoxidase, lysozyme and lactoferrin in elderly patients with dry mouth--a pilot study. , 2008, Gerodontology.

[12]  L. Berk.  Systemic pilocarpine for treatment of xerostomia. , 2008, Expert opinion on drug metabolism & toxicology.

[13]  J. Y. Wick.  Xerostomia: causes and treatment. , 2007, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[14]  Christopher U. Jones,et al.  Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[15]  P. Delaere,et al.  Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia , 2007, Supportive Care in Cancer.

[16]  T. van Achterberg,et al.  The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. , 2006, European journal of cancer care.

[17]  I. N. Steen,et al.  A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. , 2005, European journal of cancer care.

[18]  J. Schulte‐Mönting,et al.  Different Saliva Substitutes for Treatment of Xerostomia Following Radiotherapy , 2005, Strahlentherapie und Onkologie.

[19]  Robert L. White,et al.  Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09. , 2003, International journal of radiation oncology, biology, physics.

[20]  J. Guggenheimer,et al.  Xerostomia: etiology, recognition and treatment. , 2003, Journal of the American Dental Association.

[21]  J. Epstein,et al.  The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. , 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[22]  T. Matsuo.  Trehalose protects corneal epithelial cells from death by drying , 2001, The British journal of ophthalmology.

[23]  A. Davies.  A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer , 2000, Palliative medicine.

[24]  J. M. Nauta,et al.  Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. , 1998, Quintessence international.

[25]  A. Davies,et al.  A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer , 1998, Palliative medicine.

[26]  J. Carpenter,et al.  Stabilization of dry phospholipid bilayers and proteins by sugars. , 1987, The Biochemical journal.